TABLE II.

Pivotal phase iii and ii trial results of monoclonal antibodies targeting inhibitors of epidermal growth factor receptor in patients with third-line metastatic colorectal cancer

Reference	Regimens	Progression-free survival (pfs) or time to progression (ttp)	Overall survival	Response rate (rr)
Cunningham et al., 2004 6	Phase ii cetuximab plus irinotecan vs. cetuximab monotherapy, all patients	Median ttp: 4.1 months (combination) 1.5 months (monotherapy) p<0.001	8.6 months (combination) 6.9 months (monotherapy) p<0.01	Partial rr: 22.9% (combination) 10.8% (monotherapy) p<0.007
Amado et al., 2008 7	Phase iii panitumumab monotherapy vs. best supportive care (bsc) alone in patients with wild-type KRAS	Median pfs: 12.3 weeks (panitumumab); 7.3 weeks (bsc) p<0.0001	No significant difference (confounded by crossover design) p<0.0001	Partial rr: 17% (panitumumab), 22% in crossover group; 0% (bsc), 12% in crossover group
Karapetis et al., 2008 8	Phase iii cetuximab monotherapy vs. bsc alone in patients with wild-type KRAS	Median pfs: 3.8 months (cetuximab); 1.9 months (bsc) p<0.0001	9.5 months (cetuximab); 4.8 months (bsc) p<0.0001	Overall rr: 12.8% (cetuximab); 0% (bsc) p<0.001